Literature DB >> 26629269

Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes.

Loretta Fala.   

Abstract

Entities:  

Year:  2015        PMID： 26629269      PMCID： PMC4665067     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  7 in total

1.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

2.  Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

Authors:  William T Cefalu; Lawrence A Leiter; Kun-Ho Yoon; Pablo Arias; Leo Niskanen; John Xie; Dainius A Balis; William Canovatchel; Gary Meininger
Journal:  Lancet       Date:  2013-07-12       Impact factor: 79.321

3.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.

Authors:  James P Boyle; Theodore J Thompson; Edward W Gregg; Lawrence E Barker; David F Williamson
Journal:  Popul Health Metr       Date:  2010-10-22

4.  American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Michael B Davidson; Daniel Einhorn; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez; Michael H Davidson
Journal:  Endocr Pract       Date:  2013 May-Jun       Impact factor: 3.443

Review 5.  Understanding the kidneys' role in blood glucose regulation.

Authors:  Curtis L Triplitt
Journal:  Am J Manag Care       Date:  2012-01       Impact factor: 2.229

6.  Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.

Authors:  F J Lavalle-González; A Januszewicz; J Davidson; C Tong; R Qiu; W Canovatchel; G Meininger
Journal:  Diabetologia       Date:  2013-09-13       Impact factor: 10.122

7.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112
  7 in total
  3 in total

Review 1.  SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.

Authors:  Katherine Donnan; Lakshman Segar
Journal:  Eur J Pharmacol       Date:  2019-01-11       Impact factor: 4.432

2.  Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.

Authors:  Alehegn Gelaye; Abdallah Haidar; Christina Kassab; Syed Kazmi; Prabhat Sinha
Journal:  Case Rep Crit Care       Date:  2016-03-21

Review 3.  Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.

Authors:  Jian Li; Yanping Gong; Chunlin Li; Yanhui Lu; Yu Liu; Yinghong Shao
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.